Rai Shinya
Department of Hematology and Rheumatology, Kindai University Hospital, Faculty of Medicine.
Rinsho Ketsueki. 2020;61(9):1266-1274. doi: 10.11406/rinketsu.61.1266.
The development of targeted therapies, such as rituximab-an anti-CD20 antibody targeting CD20, has undergone a paradigm shift from conventional chemotherapy for malignant lymphoma (ML). Although a subset of ML patients has been cured, the treatment of refractory and relapsed diseases remains challenging. Fortunately, growing insights on molecular biology for ML have led to the development of a number of innovative agents. Moreover, a plethora of targeted therapies, including novel antibodies targeting surface antigens, and small molecular inhibitors targeting oncogenic signaling pathways, tumor suppressors, and epigenetic regulation are currently under investigation for the improvement of dismal prognosis. In addition, immunotherapies, including immune checkpoint inhibitors, bispecific T-cell engager antibodies, and chimeric antigen receptor T-cells for ML have been rapidly developed to target tumor microenvironment. These promising mechanism-based targeted therapies could lead to a successful ML management.
靶向治疗的发展，如利妥昔单抗（一种靶向CD20的抗CD20抗体），已经经历了从传统化疗治疗恶性淋巴瘤（ML）的模式转变。尽管一部分ML患者已被治愈，但难治性和复发性疾病的治疗仍然具有挑战性。幸运的是，对ML分子生物学的深入了解促使了许多创新药物的开发。此外，大量的靶向治疗，包括靶向表面抗原的新型抗体以及靶向致癌信号通路、肿瘤抑制因子和表观遗传调控的小分子抑制剂，目前正在进行研究以改善不良预后。此外，免疫疗法，包括用于ML的免疫检查点抑制剂、双特异性T细胞衔接抗体和嵌合抗原受体T细胞，已迅速发展以靶向肿瘤微环境。这些基于机制的有前景的靶向治疗可能会带来成功的ML治疗。
